Hims & Hers Acquires US-based Peptide Facility in California
February 21, 2025
Hims & Hers Health, Inc. has acquired a US-based peptide manufacturing facility in California to further verticalize its supply chain and expand domestic capabilities for personalized medications. The acquisition, which closed in early February, strengthens Hims & Hers’ ability to meet growing consumer demand for personalized healthcare and peptide-based treatments.
- Buyers
- Hims & Hers Health, Inc.
- Targets
- US-based peptide facility (unnamed)
- Industry
- Pharmaceuticals
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Hims & Hers Acquires Honest Health to Expand UK Footprint
June 14, 2021
Healthcare Services
Hims & Hers Health, Inc. agreed to acquire London-based vertical health platform Honest Health to accelerate the company's expansion into the United Kingdom and Western Europe. The acquisition adds Honest Health’s hair-loss telehealth clinic and compounding pharmacy/fulfillment capabilities to Hims & Hers’ multi-specialty telehealth platform; financial terms were not disclosed.
-
Hims & Hers Acquires Apostrophe
June 24, 2021
Healthcare Services
Hims & Hers Health, Inc. completed the acquisition of teledermatology specialist Apostrophe to deepen its personalized dermatology offering and integrate Apostrophe's clinical team and compounding pharmacy capabilities. The entire Apostrophe team will join Hims & Hers, with Apostrophe CEO Ben Holber becoming head of Hims & Hers' dermatology business line.
-
Hims & Hers Acquires MedisourceRx from Nivagen Pharmaceuticals
September 12, 2024
Pharmaceuticals
Hims & Hers has acquired MedisourceRx, the FDA-registered 503B outsourcing facility and business unit of Nivagen Pharmaceuticals. Bourne Partners served as exclusive financial adviser to Nivagen; proceeds from the sale will allow Nivagen to complete a sterile injectables facility in California and advance its pipeline.
-
Hims & Hers to Go Public via Merger with Oaktree Acquisition Corp.
October 1, 2020
Healthcare Services
Hims & Hers (Hims, Inc.), a multi-specialty telehealth and consumer health platform, entered a definitive merger agreement with SPAC Oaktree Acquisition Corp. The business combination values the combined company at an approximate $1.6 billion enterprise value and provides up to $280 million of cash (including a $75 million PIPE led by Franklin Templeton and certain Oaktree clients) to accelerate Hims & Hers' growth and expansion into new care categories.
-
Biosynth Acquires Pepceuticals to Add Multi-Kilogram GMP Peptide Manufacturing
September 25, 2023
Pharmaceuticals
Biosynth has acquired Pepceuticals, a UK-based specialist in synthetic peptides with multi-kilogram GMP and fill-finish capabilities. The deal expands Biosynth’s peptide division and enables end-to-end support from discovery through clinical trials to commercial supply.
-
Hims & Hers Acquires ZAVA
June 3, 2025
Healthcare Services
Hims & Hers Health, Inc. agreed to acquire ZAVA, a leading European digital health and telemedicine platform, in an all-cash transaction to accelerate the company's expansion into the UK and launch operations in Germany, France and Ireland. The acquisition brings ZAVA’s ~1.3 million active customers and nearly 2.3 million consultations in 2024 onto Hims & Hers’ platform and is expected to be accretive by 2026.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.